Validation of an RLIP76 Assay in Humans
Type 2 Diabetes

About this trial
This is an interventional diagnostic trial for Type 2 Diabetes focused on measuring Type 2 diabetes, metabolic syndrome, oxidative stress, GSH
Eligibility Criteria
Inclusion Criteria:
- Registered patient of City of Hope and followed in the Endocrine Clinic. Must have documentation of a diagnosis of diabetes identified by the problem list in the patient's electronic health record.
Must demonstrate features of MsY by possessing any of the following characteristics and/or receiving treatment for diabetes, hyperlipidemia, and/or hypertriglyceridemia.
- Central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 36 inches (female)
- Dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl)
- Dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female)
- Blood pressure ≥ 130/85 mmHg
- Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)
Sites / Locations
- City of Hope Medical Center
Arms of the Study
Arm 1
Other
Blood Draw
Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting